FRI is pleased to announce that Drs. Michael S. Gordon (MPI) and Thomas R. Blue (Co-I), along with Dr. Lauren Brinkley-Rubinstein (MPI, contact) Associate Professor in the Department of Population Health Sciences at Duke University and Dr. Curt Beckwith (MPI) from The Miriam Hospital/Rhode Island Hospital and Alpert Medical School at Brown University have received funding from the National Institute on Drug Abuse through the “Ending the HIV Epidemic: Focus on Justice Populations with SUD” R61/R33 Clinical Trial grant mechanism. The project titled, “NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings” proposes to conduct a hybrid implementation-effectiveness type 2 study to optimize and test the efficacy of a LAI PrEP + buprenorphine (XR-B) co-packaged intervention among people in carceral and community re-entry settings in Ending the Epidemic Sites in Maryland and Washington, DC. The study specific aims are: Aim 1 (R61): Develop the intervention protocol for delivery of LAI PrEP + XR-B; Aim 2 (R33): Evaluate implementation facilitation as a strategy to support co-located LAI PrEP + XR-B in carceral and re-entry settings; and Aim 3 (R33): Compare the effectiveness of LAI PrEP + XR-B to oral PrEP + SL-B. Our long-term goal is to 1) provide guidance on how to implement LAI interventions in these settings; and 2) generate evidence relevant to the efficacy of co packaging LAI PrEP + XR-B to improve adherence and continuation of PrEP and buprenorphine.